A clinical trial has found that a dose of psilocybin brings sustained reductions in depression and anxiety in cancer patients. The psychedelic compound from “magic” mushrooms could be repeated to treat depression in patients, suggest researchers. Published in American Cancer Society, the study reveals that many people with cancer suffer from depression, which is why in the phase two trial, 28 patients with cancer and major depressive disorder were given a single 25 mg dose of psilocybin. They received psychological support from a therapist before, during, and following the dose.
